Susquehanna International Group, LLP Pharma Cyte Biotech, Inc. Transaction History

Susquehanna International Group, LLP

$688 Billion
Q2 2025

A detailed history of Susquehanna International Group, LLP transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 27,606 shares of PMCB stock, worth $29,814. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,606

Previous 18,406 49.98%

Holding current value

$29,814

Previous $23,000 30.43%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.01 - $1.3 $9,292 - $11,960	9,200 Added 49.98%	27,606 $30,000
Q1 2025 May 14, 2025	SELL	$1.25 - $1.86 $20,093 - $29,899	-16,075 Reduced 46.62%	18,406 $23,000
Q4 2024 Feb 14, 2025	SELL	$1.55 - $2.16 $1,157 - $1,613	-747 Reduced 2.12%	34,481 $53,000
Q3 2024 Nov 14, 2024	SELL	$1.47 - $2.18 $28,820 - $42,741	-19,606 Reduced 35.76%	35,228 $67,000
Q2 2024 Aug 15, 2024	BUY	$1.95 - $2.52 $26,609 - $34,387	13,646 Added 33.13%	54,834 $107,000
Q1 2024 May 07, 2024	BUY	$1.95 - $2.48 $37,362 - $47,516	19,160 Added 86.98%	41,188 $97,000
Q4 2023 Feb 14, 2024	BUY	$2.01 - $2.34 $44,276 - $51,545	22,028 New	22,028 $47,000
Q1 2023 May 16, 2023	BUY	$2.83 - $3.03 $302,487 - $323,864	106,886 New	106,886 $311,000
Q3 2022 Nov 14, 2022	SELL	$2.24 - $2.85 $138,846 - $176,657	-61,985 Reduced 78.85%	16,624 $40,000
Q2 2022 Aug 15, 2022	BUY	$1.99 - $2.33 $100,588 - $117,774	50,547 Added 180.13%	78,609 $178,000
Q1 2022 May 16, 2022	BUY	$1.91 - $2.77 $53,598 - $77,731	28,062 New	28,062 $65,000

Others Institutions Holding PMCB

# of Institutions

Shares Held

682K

Call Options Held

Put Options Held

View Full List

About PharmaCyte Biotech, Inc.

Ticker PMCB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,750,100
Market Cap $22.4M
Description
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...

More about PMCB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Pharma Cyte Biotech, Inc. Transaction History